Back to top

Quidel (QDEL) Worth a Look: Stock Jumps 25.4% in Session
July 18, 2017

Read MoreHide Full Article

Quidel Corporation (QDEL - Free Report) was a big mover last session, as the company saw its shares jump above 25% on the day. The upside was driven by company’s announcement to acquire the Triage MeterPro cardiovascular and toxicology assets, and the B-type Naturietic Peptide assay business run on Beckman Coulter analyzers from Alere Inc. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 34% in the past one-month time frame.

The company has seen no positive or negative estimate revision in the past 30 days. Also, its Zacks Consensus Estimate remained unchanged over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Quidel Corporation currently holds a Zacks Rank #2 (Buy).

Quidel Corporation Price

 

Another top-ranked stock in the Medical - Products industry is OraSure Technologies, Inc. (OSUR - Free Report) , which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is QDEL going up? Or down? Predict to see what others think: Up or Down

5 Trades Could Profit ""Big-League"" from Trump Policies                                                                                                            

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


OraSure Technologies, Inc. (OSUR) - free report >>

Quidel Corporation (QDEL) - free report >>


More from Zacks Tale of the Tape

You May Like